Testicular Cancer Clinical Trial
Official title:
Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell
Germ cell tumors belong to the most chemosensitive malignancies. Paclitaxel in combination with ifosfamide and cisplatin (TIP) has become a common regimen for salvage treatment of germ cell cancer. Cabazitaxel may overcome resistance to docetaxel and paclitaxel and might have clinical activity in patients with metastatic and progressive germ cell tumors.
Patients with metastatic germ cell cancer and relapse after two or more courses of cisplatin-based chemotherapy or after high-dose chemotherapy have a poor prognosis and no curative options. Taxanes in various combinations unfold cytotoxic effects on germ cell tumors resistant to conventional doses of cisplatin. Paclitaxel in combination with ifosfamide and cisplatin (TIP) has become a common regimen for salvage treatment of germ cell cancer. In most patients, however, resistance to paclitaxel, as evidenced by progression occurs.Cabazitaxel has been developed to overcome resistance to docetaxel and paclitaxel. It has shown efficacy in patients progressing during docetaxel therapy in a large phase III trial (TROPIC) in patients with castration-resistant prostate cancer. Furthermore, chemotherapy resistance might be less likely to develop in patients receiving cabazitaxel as compared to other taxanes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT00772694 -
Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy
|
Phase 2 | |
| Completed |
NCT00705094 -
Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients
|
N/A | |
| Terminated |
NCT00531687 -
Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer
|
Phase 2 | |
| Terminated |
NCT00820287 -
Identification of Predictive Markers for Testis Cancer in a Population of Men With High Risk
|
N/A | |
| Completed |
NCT00216801 -
Relationship of Ochratoxin A to Upper Urologic Cancers
|
N/A | |
| Active, not recruiting |
NCT03142802 -
Low-Dose CT - Stage I Testicular Cancer
|
N/A | |
| Recruiting |
NCT03232541 -
The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting
|
N/A | |
| Completed |
NCT03557177 -
Clinical Characterisation of the Vascular Effects of Cis-platinum Based Chemotherapy in Patients With Testicular Cancer
|
||
| Recruiting |
NCT02573584 -
Vascular Fingerprint Validation Study
|
||
| Active, not recruiting |
NCT01783145 -
Shared Care Follow-up After Chemotherapy for Testicular Cancer
|
||
| Recruiting |
NCT05611307 -
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
|
||
| Recruiting |
NCT05670938 -
Follow-up After Surgery for Testicular Cancer
|
||
| Recruiting |
NCT02994758 -
Development of Diagnostics and Treatment of Urological Cancers
|
N/A | |
| Completed |
NCT02991209 -
Study of Testosterone vs Placebo in Testicular Cancer Survivors
|
Phase 2/Phase 3 | |
| Completed |
NCT02602041 -
Knowledge and Attitudes Regarding Healthy Lifestyle and Health Behavior Change in Cancer Patients and Their Partners; A Pilot Study
|
||
| Completed |
NCT02092740 -
REtrospective Study of TESTIcular CAncer Patients at the University Magdeburg
|
N/A | |
| Completed |
NCT01482741 -
Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging
|
N/A | |
| Active, not recruiting |
NCT01242072 -
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
|
Phase 1 | |
| Completed |
NCT01242631 -
Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer
|
Phase 2 | |
| Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A |